Osteoporosis drug found safe in long-term trial
A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 17, 2017 Category: Science Source Type: news
Study finds osteoporosis drug safe in long-term trial
Researchers have determined the osteoporosis drug denosumab is safe and effective at treating osteoporosis and preventing bone fractures. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 17, 2017 Category: Consumer Health News Source Type: news
Osteoporosis drug found safe in long-term trial
(Wiley) A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2017 Category: Global & Universal Source Type: news
Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients
Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications
THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma Workshop (IMW...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Bone Loss Resumes When Long-term Denosumab Therapy Stops Bone Loss Resumes When Long-term Denosumab Therapy Stops
Bone loss resumes during the year following discontinuation of long-term denosumab therapy, although it is attenuated in patients who begin another osteoporosis therapy.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 15, 2017 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include:
For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion.
Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib).
For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth.
GAAP earnings per share (EPS) increased 9 percent in the fourth quarter to $2....
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis
THOUSAND OAKS, Calif., Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), as well as investigational candidates, including ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Wa...
Source: Amgen News Release - November 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Xgeva May Boost Bone Erosion Repair in RA (CME/CE)
(MedPage Today) -- Denosumab/DMARD combination should be considered (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 31, 2016 Category: Geriatrics Source Type: news
FRAME: Romosozumab Rapidly Reduces Fracture Risk in Osteoporosis FRAME: Romosozumab Rapidly Reduces Fracture Risk in Osteoporosis
Romosozumab rapidly and dramatically reduces vertebral fractures compared with placebo in FRAME, and bone-enhancing effects continue after patients are transitioned to denosumab for a further year.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 19, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months
Significant Bone Mineral Density Gains Shown at Six and 12 Months at the Lumbar Spine, Total Hip and Femoral Neck
Bone Mineral Density Continued to Increase and Vertebral Fracture Risk Reduction Persisted With the Transition From Romosozumab to Denosumab Through 24 Months
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 18, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced findi...
Source: Amgen News Release - September 18, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis
Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis
THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. 16-19, 201...
Source: Amgen News Release - September 17, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
